Deine Cell Cultures, an welchem Börsenplatz könntest Du denn kaufen?
Meine angesprochenen AMDL heute mit neuem 52-Wochen-Hoch und 20 % Kursgewinn, fangen an nach Australien und Neusseland zu verkaufen.
Gruss E.
chart.bigcharts.com/bc3/quickchart/...55&mocktick=1&rand=4414"
AMDL's DR-70(R) Begins Sale in Australia, New Zealand
MONDAY, JULY 21, 2003 2:16 PM
- PR Newswire
TUSTIN, Calif. and VICTORIA, Australia, Jul 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- AMDL, Inc. (ADL) today announced that AMDL Australia Pty. Ltd., AMDL's distributor, has begun the sale of the DR-70(R) cancer detection test in Australia and New Zealand. Australia's Therapeutic Goods Administration (TGA) previously granted approval to market DR-70(R) to the Australian company.
AMDL Australia Pty. Ltd., which is not affiliated with AMDL in the U.S., is AMDL's exclusive distributor of the DR-70(R) blood test in Australia and New Zealand. Anna-Louise Brown, Director of AMDL Australia, said, "Australia and New Zealand, with combined populations of more than 20 million, are very sophisticated countries with superior health care systems. We believe they will be an excellent marketplace for DR-70(R)."
DR-70(R) is a non-intrusive blood test that can detect and monitor 13 types of cancer from a single 2ml blood serum sample. These cancers include cervical, breast, lung, colon, liver, stomach and malignant lymphoma. Studies published in the Journal of Immunoassay determined that DR-70(R) demonstrated its ability to detect the presence of cancers in humans 84% of the time. Clinical trials of DR-70(R) have been conducted in Germany, China, Canada, Turkey and Taiwan. DR-70(R) can detect cancer using a single tube of blood, eliminating the need for costly, multiple tests.
"While we are focused on getting our product cleared to sell in the U.S. at this time, it is still crucial for AMDL to continue to find excellent potential markets overseas," said Gary L. Dreher, AMDL President. "We are confident that Australia and New Zealand will be a strong marketplace for DR-70(R)."
About AMDL:
AMDL, Inc. (ADL) , headquartered in Tustin, California, is a theranostics company, involved in both the detection and treatment of the same disease, cancer. AMDL is the inventor and developer of the DR-70(R) non-invasive cancer blood test. DR-70(R) has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 percent of the time overall. Clinical trials of DR-70(R) have been conducted in Germany, China, Canada, Taiwan and Turkey. Cancers that can be detected are lung, colon, breast, stomach, liver, rectal, ovarian, cervical, esophageal, thyroid, pancreatic, trophoblastic and malignant lymphoma. DR-70(R) can detect many kinds of cancer using a single tube of blood, eliminating the need for costly, multiple tests. AMDL has recently received approval from the Health Protection Agency to market DR-70(R) in Canada. AMDL makes DR-70(R) available worldwide through exclusive distribution agreements. AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The technology both builds the body's immune system and destroys cancer cells. AMDL recently contracted with the University of Florida to begin studies of breast cancer using the combination immunogene therapy technology. More information about AMDL and its additional products can be obtained at
www.amdlcorporate.com .
Forward-Looking Statements
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
SOURCE AMDL, Inc.
Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460,
or Anna-Louise Brown of AMDL Australia Pty. Ltd., 03 9762 9015,
enq@amdlaustralia.com.au
www.amdlcorporate.com 
